AMLX Stock Price, Amylyx Pharmaceuticals, . Quote, Chart

Market Summary

USD2.08-0.02

Market Closed

-0.95%

AMLX Stock Price

View Fullscreen

AMLX RSI Chart

AMLX Valuation

Market Cap

141.0M

Price/Earnings (Trailing)

2.86

Price/Sales (Trailing)

0.37

EV/EBITDA

-0.53

Price/Free Cashflow

13.2

AMLX Price/Sales (Trailing)

AMLX Profitability

EBT Margin

14.26%

Return on Equity

11.37%

Return on Assets

9.52%

Free Cashflow Yield

7.57%

AMLX Fundamentals

AMLX Revenue

Revenue (TTM)

380.8M

Rev. Growth (Yr)

102.17%

Rev. Growth (Qtr)

5.61%

AMLX Earnings

Earnings (TTM)

49.3M

Earnings Growth (Yr)

111.08%

Earnings Growth (Qtr)

-77.36%

Breaking Down AMLX Revenue

Last 7 days

-22.7%

Last 30 days

-35.8%

Last 90 days

-86.6%

Trailing 12 Months

-93.1%

How does AMLX drawdown profile look like?

AMLX Financial Health

Current Ratio

5.66

AMLX Investor Care

Shares Dilution (1Y)

1.91%

Diluted EPS (TTM)

0.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	111.9M	201.5M	291.1M	380.8M
2022	0	0	11.3M	22.2M
2021	0	0	0	285.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Amylyx Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	klee justin b.	sold	-77,439	18.7279	-4,135	co-chief executive officer
Mar 05, 2024	mazzariello gina	sold	-28,841	18.7279	-1,540	chief legal officer
Mar 05, 2024	frates james m	sold	-33,560	18.7279	-1,792	chief financial officer
Mar 05, 2024	cohen joshua b	sold	-77,439	18.7279	-4,135	co-chief executive officer
Feb 26, 2024	mazzariello gina	acquired	-	-	36,667	chief legal officer
Feb 26, 2024	cohen joshua b	acquired	-	-	126,667	co-chief executive officer
Feb 26, 2024	klee justin b.	acquired	-	-	126,667	co-chief executive officer
Feb 26, 2024	frates james m	acquired	-	-	40,000	chief financial officer
Feb 23, 2024	mazzariello gina	sold	-53,230	18.7564	-2,838	chief legal officer
Jan 25, 2024	milne george m jr	gifted	-	-	-9,100	-

Which funds bought or sold AMLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Dynamic Advisor Solutions LLC	added	9.59	488,219	3,367,520	0.11%
Apr 12, 2024	Global Assets Advisory, LLC	new	-	2,000,000	2,000,000	0.09%
Apr 12, 2024	First PREMIER Bank	reduced	-22.96	-7,000	110,000	0.03%
Apr 12, 2024	High Net Worth Advisory Group LLC	new	-	258,008	258,008	0.08%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	699	11,664	-%
Apr 12, 2024	Pacifica Partners Inc.	new	-	7,996	7,996	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	1,807	24,676	-%
Apr 12, 2024	Pacifica Partners Inc.	unchanged	-	-348	4,681	-%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-2,940	-	-%
Apr 12, 2024	AdvisorNet Financial, Inc	reduced	-35.04	-275	1,982	-%

Are Funds Buying or Selling AMLX?

Are funds buying AMLX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMLX

No. of Funds

Unveiling Amylyx Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	panacea innovation ltd	6.2%	4,200,000	SC 13G
Feb 14, 2024	point72 asset management, l.p.	4.1%	2,751,305	SC 13G/A
Feb 14, 2024	perceptive advisors llc	2.8%	1,869,125	SC 13G/A
Feb 14, 2024	viking global investors lp	4.4%	2,962,555	SC 13G/A
Feb 13, 2024	vanguard group inc	7.81%	5,275,566	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	4,002,334	SC 13G
Dec 11, 2023	point72 asset management, l.p.	4.7%	3,176,105	SC 13G
Oct 04, 2023	morningside venture investments ltd	3.43%	2,313,227	SC 13D/A
Aug 17, 2023	morningside venture investments ltd	6.86%	4,618,846	SC 13D/A
Jun 09, 2023	goldman sachs group inc	5.4%	3,653,782	SC 13G

Recent SEC filings of Amylyx Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Mar 15, 2024	3	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 14, 2024	8-K	Current Report
Mar 11, 2024	SC 13G	Major Ownership Report
Mar 08, 2024	8-K	Current Report
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading

Peers (Alternatives to Amylyx Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Amylyx Pharmaceuticals, Inc. News

Latest updates

Amylyx Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3
Revenue	5.6%	108,449,000	102,693,000	98,216,000	71,428,000	53,642,250	35,856,500	18,070,750	285,000
Costs and Expenses	26.8%	106,515,000	83,973,000	78,015,000	73,481,000	66,478,000	55,026,000	-	23,203,000
S&GA Expenses	7.2%	52,241,000	48,718,000	43,391,000	44,006,000	40,844,000	29,940,000	14,921,000	10,350,000
R&D Expenses	49.5%	44,914,000	30,037,000	29,044,000	24,192,000	22,813,000	24,914,000	13,394,000	12,853,000
EBITDA Margin	535.4%	0.15	0.02	-0.35	-1.32	-8.87	-10.96	-308	-
Income Taxes	17.0%	1,776,500	1,518,000	1,900,000	-200,000	553,500	-100,000	-	-
Earnings Before Taxes	-71.1%	6,476,000	22,411,000	24,007,000	1,403,000	-42,125,000	-53,881,000	-28,344,000	-23,142,000
EBT Margin	628.8%	0.14	0.02	-0.35	-1.33	-8.89	-10.98	-308	-
Net Income	-77.4%	4,731,000	20,893,000	22,074,000	1,573,000	-42,704,000	-53,756,000	-28,344,000	-23,142,000
Net Income Margin	1951.9%	0.13	0.01	-0.36	-1.33	-8.92	-10.99	-308	-
Free Cashflow	338.8%	13,195,000	-5,526,000	8,331,000	-5,322,000	-50,317,000	-43,537,000	-28,430,000	-21,018,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet									(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	10.9%	517	467	454	408	391	181	225	274	106
Current Assets	7.0%	465	434	427	389	382	172	216	265	105
Cash Equivalents	25.8%	170	135	248	115	63.00	108	67.00	110	50.00
Inventory	18.4%	38.00	32.00	25.00	13.00	10.00	1.00	-	-	-
Net PPE	-2.7%	3.00	3.00	3.00	3.00	3.00	2.00	2.00	1.00	0.00
Liabilities	74.4%	84.00	48.00	67.00	55.00	51.00	37.00	32.00	33.00	17.00
Current Liabilities	79.8%	82.00	46.00	64.00	52.00	47.00	33.00	27.00	28.00	17.00
Shareholder's Equity	3.6%	433	418	386	353	341	144	193	241	-151
Retained Earnings	1.5%	-304	-309	-330	-352	-354	-311	-257	-203	-155
Additional Paid-In Capital	1.4%	738	728	717	705	695	456	451	445	5.00
Shares Outstanding	0.3%	68.00	68.00	67.00	67.00	67.00	59.00	58.00	52.00	7.00
Float	-	-	-	1,310	-	-	-	788	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	362.2%	13,551	-5,169	8,609	-5,072	-49,697	-43,078	-46,462	-40,634	-28,244	-20,865	-13,047	-12,643
Share Based Compensation	-6.3%	9,534	10,176	9,950	7,501	6,091	5,524	5,707	4,392	1,091	802	657	586
Cashflow From Investing	119.4%	20,925	-108,088	123,222	55,994	-228,180	84,041	4,462	-99,311	2,814	-49,206	-	-14.00
Cashflow From Financing	-74.1%	230	889	1,384	1,040	232,162	-	-828	200,455	-1,065	131,651	1,993	25,927

AMLX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Product revenue, net	$ 380,786	$ 22,230
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Grant revenue			$ 285
Total revenues	$ 380,786	$ 22,230	285
Operating expenses:
Cost of sales	25,441	2,993
Research and development	128,187	93,450	44,040
Selling, general and administrative	188,356	127,128	38,933
Total operating expenses	341,984	223,571	82,973
Income (loss) from operations	38,802	(201,341)	(82,688)
Other income (expense), net:
Interest income	16,155	4,291	36
Change in fair value of convertible notes			(5,228)
Other expense, net	(660)	(551)	(51)
Total other income (expense), net	15,495	3,740	(5,243)
Income (loss) before income taxes	54,297	(197,601)	(87,931)
Provision for income taxes	5,026	774
Net income (loss)	$ 49,271	$ (198,375)	$ (87,931)
Net income (loss) per share-basic	$ 0.73	$ (3.39)	$ (13.35)
Net income (loss) per share-diluted	$ 0.7	$ (3.39)	$ (13.35)
Weighted-average shares used in computing net income (loss) per share-basic	67,234,465	58,495,587	6,586,349
Weighted-average shares used in computing net income (loss) per share-diluted	69,991,340	58,495,587	6,586,349

AMLX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 170,201	$ 62,526
Short-term investments	201,161	284,419
Accounts receivable, net	40,050	15,306
Inventories	38,323	9,769
Prepaid expenses and other current assets	14,931	10,113
Total current assets	464,666	382,133
Property and equipment, net	2,686	2,611
Restricted cash equivalents	719	719
Operating lease right-of-use assets	3,725	5,524
Long-term inventories	44,957
Other assets	701	466
Total assets	517,454	391,453
Current liabilities:
Accounts payable	22,061	6,257
Accrued expenses	57,724	38,312
Operating lease liabilities, current portion	2,257	2,040
Total current liabilities	82,042	46,609
Operating lease liabilities, net of current portion	1,980	4,237
Total liabilities	84,022	50,846
Commitments and contingencies (Note 18)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized
Common stock, $0.0001 par value; 300,000,000 shares authorized; 67,707,432 and 66,512,011 shares issued and outstanding as of December 31, 2023 and 2022, respectively	7	7
Additional paid-in capital	738,177	694,906
Accumulated deficit	(304,949)	(354,220)
Accumulated other comprehensive income (loss)	197	(86)
Total stockholders"equity	433,432	340,607
Total liabilities, redeemable convertible preferred stock and stockholders' equity	$ 517,454	$ 391,453

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Joshua B. Cohen
WEBSITE	https://amylyx.com
INDUSTRY	Biotechnology
EMPLOYEES	338

Amylyx Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Amylyx Pharmaceuticals, Inc.? What does AMLX stand for in stocks?

AMLX is the stock ticker symbol of Amylyx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amylyx Pharmaceuticals, Inc. (AMLX)?

As of Mon Apr 15 2024, market cap of Amylyx Pharmaceuticals, Inc. is 140.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers. The fair value of Amylyx Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amylyx Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amylyx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether AMLX is over valued or under valued. Whether Amylyx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Amylyx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMLX.

What is Amylyx Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, AMLX's PE ratio (Price to Earnings) is 2.86 and Price to Sales (PS) ratio is 0.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMLX PE ratio will change depending on the future growth rate expectations of investors.